by Véronique DUPONT Agence France Presse Only a few weeks ago, Anglo-Swedish pharmaceutical giant AstraZeneca was being applauded for the speed with which it developed its Covid-19 vaccine. Experts heralded the launch of the jab as a turning point in the pandemic, not least because it can be transported and stored more easily than its Pfizer/BioNTech counterpart. The Anglo-Swedish firm also won plaudits for promising to provide the vaccine on a non-profit basis to […]
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.